These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

720 related articles for article (PubMed ID: 26198719)

  • 1. Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset.
    Chan JF; Yao Y; Yeung ML; Deng W; Bao L; Jia L; Li F; Xiao C; Gao H; Yu P; Cai JP; Chu H; Zhou J; Chen H; Qin C; Yuen KY
    J Infect Dis; 2015 Dec; 212(12):1904-13. PubMed ID: 26198719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial.
    Arabi YM; Alothman A; Balkhy HH; Al-Dawood A; AlJohani S; Al Harbi S; Kojan S; Al Jeraisy M; Deeb AM; Assiri AM; Al-Hameed F; AlSaedi A; Mandourah Y; Almekhlafi GA; Sherbeeni NM; Elzein FE; Memon J; Taha Y; Almotairi A; Maghrabi KA; Qushmaq I; Al Bshabshe A; Kharaba A; Shalhoub S; Jose J; Fowler RA; Hayden FG; Hussein MA;
    Trials; 2018 Jan; 19(1):81. PubMed ID: 29382391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome.
    Kim UJ; Won EJ; Kee SJ; Jung SI; Jang HC
    Antivir Ther; 2016; 21(5):455-9. PubMed ID: 26492219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets.
    de Wit E; Feldmann F; Okumura A; Horne E; Haddock E; Saturday G; Scott D; Erlandson KJ; Stahl N; Lipsich L; Kyratsous CA; Feldmann H
    Antiviral Res; 2018 Aug; 156():64-71. PubMed ID: 29885377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial.
    Arabi YM; Asiri AY; Assiri AM; Aziz Jokhdar HA; Alothman A; Balkhy HH; AlJohani S; Al Harbi S; Kojan S; Al Jeraisy M; Deeb AM; Memish ZA; Ghazal S; Al Faraj S; Al-Hameed F; AlSaedi A; Mandourah Y; Al Mekhlafi GA; Sherbeeni NM; Elzein FE; Almotairi A; Al Bshabshe A; Kharaba A; Jose J; Al Harthy A; Al Sulaiman M; Mady A; Fowler RA; Hayden FG; Al-Dawood A; Abdelzaher M; Bajhmom W; Hussein MA;
    Trials; 2020 Jan; 21(1):8. PubMed ID: 31900204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study.
    Shalhoub S; Farahat F; Al-Jiffri A; Simhairi R; Shamma O; Siddiqi N; Mushtaq A
    J Antimicrob Chemother; 2015 Jul; 70(7):2129-32. PubMed ID: 25900158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
    Sheahan TP; Sims AC; Leist SR; Schäfer A; Won J; Brown AJ; Montgomery SA; Hogg A; Babusis D; Clarke MO; Spahn JE; Bauer L; Sellers S; Porter D; Feng JY; Cihlar T; Jordan R; Denison MR; Baric RS
    Nat Commun; 2020 Jan; 11(1):222. PubMed ID: 31924756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
    Momattin H; Al-Ali AY; Al-Tawfiq JA
    Travel Med Infect Dis; 2019; 30():9-18. PubMed ID: 31252170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Acute Immune Response to Middle East Respiratory Syndrome Coronavirus Replication Contributes to Viral Pathogenicity.
    Baseler LJ; Falzarano D; Scott DP; Rosenke R; Thomas T; Munster VJ; Feldmann H; de Wit E
    Am J Pathol; 2016 Mar; 186(3):630-8. PubMed ID: 26724387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of treatment effect of interferon-β1b and lopinavir-ritonavir in patients with Middle East respiratory syndrome by cytokine levels.
    Arabi YM; Asiri AY; Assiri AM; Abdullah ML; Aljami HA; Balkhy HH; Al Jeraisy M; Mandourah Y; AlJohani S; Al Harbi S; Jokhdar HAA; Deeb AM; Memish ZA; Jose J; Ghazal S; Al Faraj S; Al Mekhlafi GA; Sherbeeni NM; Elzein FE; Hayden FG; Fowler RA; AlMutairi BM; Al-Dawood A; Alharbi NK
    Sci Rep; 2022 Oct; 12(1):18186. PubMed ID: 36307462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
    Vargas M; Servillo G; Einav S
    Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.
    Rabaan AA; Alahmed SH; Bazzi AM; Alhani HM
    J Med Microbiol; 2017 Sep; 66(9):1261-1274. PubMed ID: 28855003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease.
    Agrawal AS; Garron T; Tao X; Peng BH; Wakamiya M; Chan TS; Couch RB; Tseng CT
    J Virol; 2015 Apr; 89(7):3659-70. PubMed ID: 25589660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative pathology of rhesus macaque and common marmoset animal models with Middle East respiratory syndrome coronavirus.
    Yu P; Xu Y; Deng W; Bao L; Huang L; Xu Y; Yao Y; Qin C
    PLoS One; 2017; 12(2):e0172093. PubMed ID: 28234937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset.
    de Wit E; Feldmann F; Horne E; Okumura A; Cameroni E; Haddock E; Saturday G; Scott D; Gopal R; Zambon M; Corti D; Feldmann H
    Antiviral Res; 2019 Mar; 163():70-74. PubMed ID: 30684561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia.
    Al Ghamdi M; Alghamdi KM; Ghandoora Y; Alzahrani A; Salah F; Alsulami A; Bawayan MF; Vaidya D; Perl TM; Sood G
    BMC Infect Dis; 2016 Apr; 16():174. PubMed ID: 27097824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparative Review of Animal Models of Middle East Respiratory Syndrome Coronavirus Infection.
    Baseler L; de Wit E; Feldmann H
    Vet Pathol; 2016 May; 53(3):521-31. PubMed ID: 26869154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Potential antiviral therapeutics for 2019 Novel Coronavirus].
    Li H; Wang YM; Xu JY; Cao B
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Mar; 43(3):170-172. PubMed ID: 32164080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2.
    Yeung ML; Yao Y; Jia L; Chan JF; Chan KH; Cheung KF; Chen H; Poon VK; Tsang AK; To KK; Yiu MK; Teng JL; Chu H; Zhou J; Zhang Q; Deng W; Lau SK; Lau JY; Woo PC; Chan TM; Yung S; Zheng BJ; Jin DY; Mathieson PW; Qin C; Yuen KY
    Nat Microbiol; 2016 Feb; 1(3):16004. PubMed ID: 27572168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b.
    Hong SI; Ryu BH; Chong YP; Lee S; Kim S; Kim HC; Hong KW; Bae IG; Cho OH
    Int J Antimicrob Agents; 2020 Aug; 56(2):106052. PubMed ID: 32544570
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 36.